Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab.
Where this comes from
- Record sourced from PubMed, PMID 22184728.
- Also identified by DOI 10.1093/infdis/jir790.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Specific mutations in respiratory syncytial virus (RSV) fusion protein can cause palivizumab resistance. We assessed the incidence of sequence polymorphisms and palivizumab resistance in clinical RSV isolates collected from immunoprophylaxis-naive subjects. Polymorphisms were identified at low frequency, and only polymorphic mutations in antigenic site A (<1% of all polymorphisms) conferred palivizumab resistance.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antiviral Agents
- Drug Resistance, Viral
- Mutation, Missense
- Respiratory Syncytial Viruses
- Viral Fusion Proteins